FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLC FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLC

The approval allows for continuous immunotherapy treatment around surgery for resectable non-small cell lung cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news